<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937417</url>
  </required_header>
  <id_info>
    <org_study_id>S0716</org_study_id>
    <secondary_id>SWOG-S0716</secondary_id>
    <nct_id>NCT00937417</nct_id>
  </id_info>
  <brief_title>S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as docetaxel, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. Giving vandetanib together with&#xD;
      docetaxel may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vandetanib given&#xD;
      together with docetaxel in treating patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To investigate the differential biological effects in tumor tissues through&#xD;
           pharmacodynamic endpoints (percent inhibition of pERK, pKDR, and pEGFR) and their&#xD;
           correlation with pharmacokinetics of vandetanib in combination with docetaxel in&#xD;
           patients with advanced solid tumors.&#xD;
&#xD;
        -  To correlate the pharmacodynamic endpoints with the pharmacokinetics of this combination&#xD;
           regimen in these patients.&#xD;
&#xD;
        -  To recommend an optimal biological dose of this combination regimen for further testing.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To correlate the pharmacokinetics with safety profiles of two dose levels of vandetanib&#xD;
           when given in combination with docetaxel.&#xD;
&#xD;
        -  To investigate scientific correlates, including serum proteomics and microvessel density&#xD;
           (CD31) and cell death (TUNEL) using tumor tissue biopsy samples taken at baseline and&#xD;
           during treatment.&#xD;
&#xD;
        -  To determine the objective response in patients with measurable disease at baseline.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour on day 1 and oral vandetanib once daily on days&#xD;
      1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity. After 6 weeks of treatment, patients who experience clinical benefit but poor&#xD;
      tolerance to docetaxel may continue treatment with vandetanib alone.&#xD;
&#xD;
      Plasma samples are collected periodically for pharmacokinetic analysis, measurement of&#xD;
      vandetanib trough levels, serum biomarker analysis, and serum proteomics. Tumor tissue&#xD;
      samples are collected at baseline and once between days 36-38 for pharmacodynamic analysis.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for up to 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn because SWOG no longer pursuing this study at this time&#xD;
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic parameters (percent inhibition of pERK, pKDR, and pEGFR)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of pharmacokinetic profile with pharmacodynamic data and treatment-related toxicities</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between scientific correlates (microvessel density, cell death, circulating endothelial cells, ERK and pERK, and serum proteomics) and treatment outcomes and other patient characteristics</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response and clinically stable disease in patients with measurable disease at baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vandetanib and docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vandetanib</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumor, including, but not&#xD;
             limited to the following:&#xD;
&#xD;
               -  Non-small cell lung cancer&#xD;
&#xD;
               -  Metastatic breast cancer&#xD;
&#xD;
               -  Hormone-refractory prostate cancer&#xD;
&#xD;
               -  Locally recurrent or metastatic head and neck cancer (including thyroid origin)&#xD;
&#xD;
          -  Disease for which no standard therapy exists&#xD;
&#xD;
          -  Tumor amenable to biopsy&#xD;
&#xD;
          -  Measurable or non-measurable disease&#xD;
&#xD;
          -  Brain metastases allowed provided patient has undergone brain irradiation (whole brain&#xD;
             or gamma knife) AND the metastases have been clinically and radiologically stable for&#xD;
             ≥ 6 weeks after completion of irradiation&#xD;
&#xD;
               -  Patients requiring corticosteroids or anticonvulsants for brain metastases must&#xD;
                  be on a stable or decreasing dose of corticosteroids and seizure free for ≥ 28&#xD;
                  days before study enrollment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod performance status 0-1&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  SGOT or SGPT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  PT/INR ≤ 1.1 times normal&#xD;
&#xD;
          -  Serum creatinine ≤ 1.8 times ULN OR measured or estimated creatinine clearance &gt; 50&#xD;
             mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Willing to undergo two tumor biopsies and blood and tissue sample submission for&#xD;
             correlative laboratory studies&#xD;
&#xD;
          -  No clinically significant cardiovascular event, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction or cerebrovascular accident within the past 3 months&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  NYHA class II-IV heart disease within the past 3 months&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Serious cardiac arrhythmia&#xD;
&#xD;
          -  No history of cardiac disease that, in the investigator's opinion, increases the risk&#xD;
             of ventricular arrhythmia&#xD;
&#xD;
          -  No history of arrhythmia that is symptomatic or requires treatment (CTCAE grade 3),&#xD;
             including any of the following:&#xD;
&#xD;
               -  Multifocal premature ventricular contractions (PVCs)&#xD;
&#xD;
               -  Bigeminy or trigeminy&#xD;
&#xD;
               -  Ventricular tachycardia&#xD;
&#xD;
               -  Uncontrolled atrial fibrillation&#xD;
&#xD;
                    -  Medically controlled atrial fibrillation allowed&#xD;
&#xD;
          -  No asymptomatic sustained ventricular tachycardia&#xD;
&#xD;
          -  No history of or evidence of any of the following on ECG:&#xD;
&#xD;
               -  History of QTc prolongation as a result from other medication that required&#xD;
                  discontinuation of that medication&#xD;
&#xD;
               -  Congenital long QT syndrome&#xD;
&#xD;
               -  First degree relative with unexplained sudden death under 40 years of age&#xD;
&#xD;
               -  Presence of left bundle branch block&#xD;
&#xD;
               -  QTc with Bazett's correction that is unmeasurable or ≥ 480 msec on screening ECG&#xD;
&#xD;
          -  No uncontrolled hypertension, defined as consistent systolic BP &gt; 160 mm Hg or&#xD;
             consistent diastolic BP &gt; 100 mm Hg despite medical management&#xD;
&#xD;
          -  No intractable nausea or vomiting&#xD;
&#xD;
          -  No concurrent active diarrhea that may affect the ability to absorb or tolerate&#xD;
             vandetanib&#xD;
&#xD;
          -  No gastrointestinal (GI) tract disease resulting in malabsorption syndrome or a&#xD;
             requirement for IV alimentation&#xD;
&#xD;
          -  No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)&#xD;
&#xD;
          -  No history of allergic reactions attributed to docetaxel or compounds of similar&#xD;
             chemical or biological composition to vandetanib, including other quinazoline&#xD;
             compounds (e.g., gefitinib or erlotinib)&#xD;
&#xD;
          -  No history of deep venous thrombosis or pulmonary embolism requiring therapeutic&#xD;
             anticoagulation&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No other concurrent uncontrolled illness, including, but not limited to the following:&#xD;
&#xD;
               -  Ongoing or serious active infection&#xD;
&#xD;
               -  Psychiatric illness or social situation that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  Prior or concurrent malignancies of other histologies within the past 5 years allowed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy (i.e., ≤ grade 2 alopecia and ≤ grade 1 toxicity from all&#xD;
             other adverse events)&#xD;
&#xD;
          -  Prior docetaxel as monotherapy or in combination with other chemotherapeutic agents&#xD;
             allowed provided there is potential clinical benefit present, in the investigator's&#xD;
             opinion, from the combination of docetaxel and vandetanib&#xD;
&#xD;
          -  No prior vandetanib&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
          -  More than 14 days since prior drugs with a short half-life (e.g., sorafenib or&#xD;
             sunitinib) (approval by study coordinator required)&#xD;
&#xD;
          -  More than 28 days since prior major surgery, chemotherapy, or radiotherapy&#xD;
&#xD;
          -  More than 28 days since prior investigational agents&#xD;
&#xD;
          -  More than 2 weeks since prior and no concurrent medications associated with a risk of&#xD;
             causing Torsades de Pointes&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation (coumadin, warfarin, or low-molecular weight&#xD;
             heparin)&#xD;
&#xD;
               -  Low-dose anticoagulation for indwelling catheter maintenance allowed&#xD;
&#xD;
          -  No concurrent medication that may cause QTc prolongation&#xD;
&#xD;
          -  No other concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or&#xD;
             any other type of therapy for the treatment of cancer, except for the following:&#xD;
&#xD;
               -  Luteinizing hormone-releasing hormone agonists&#xD;
&#xD;
               -  Bisphosphonates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Mita, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Therapy and Research Center, Texas</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>July 10, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>anaplastic thyroid cancer</keyword>
  <keyword>stage IV follicular thyroid cancer</keyword>
  <keyword>insular thyroid cancer</keyword>
  <keyword>stage IV papillary thyroid cancer</keyword>
  <keyword>recurrent thyroid cancer</keyword>
  <keyword>thyroid gland medullary carcinoma</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>hormone-resistant prostate cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

